A white paper on a neurodevelopmental framework for drug discovery in autism and other neurodevelopmental disorders - ScienceDirect
Signalling pathways in autism spectrum disorder: mechanisms and therapeutic implications | Signal Transduction and Targeted Therapy
Balovaptan: An Atypical Benzodiazepine With Unique Medicinal Potential - Tripsitter
Biomedicines | Free Full-Text | The Biology of Vasopressin
PDF) Balovaptan
Balovaptan: An Atypical Benzodiazepine With Unique Medicinal Potential - Tripsitter
Discovery of Balovaptan, a Vasopressin 1a Receptor Antagonist for the Treatment of Autism Spectrum Disorder | Journal of Medicinal Chemistry
Frontiers | Untangle the Multi-Facet Functions of Auts2 as an Entry Point to Understand Neurodevelopmental Disorders
Targeting antidiuretic hormone vasopressin shows promise for autism
Balovaptan and Autism Spectrum Disorder
Balovaptan Archives - CmaxInsight
48.4 VASOPRESSIN RECEPTOR ANTAGONISM AS A POTENTIAL TREATMENT OPTION FOR THE CORE SYMPTOMS OF ASD: RESULTS OF BALOVAPTAN FROM EA
Efficacy and safety of balovaptan for socialisation and communication difficulties in autistic adults in North America and Europe: a phase 3, randomised, placebo-controlled trial - The Lancet Psychiatry
Frontiers | Histamine, Neuroinflammation and Neurodevelopment: A Review
Decoding microRNAs in autism spectrum disorder: Molecular Therapy - Nucleic Acids
Bioavailability and pharmacokinetic profile of balovaptan, a selective, brain-penetrant vasopressin 1a receptor antagonist, in h
Optimism, confusion greet federal fast track for autism drug
Balovaptan | ≥99%(HPLC) | hV1a receptor antagonist | AdooQ®
Signalling pathways in autism spectrum disorder: mechanisms and therapeutic implications | Signal Transduction and Targeted Therapy
Balovaptan - Wikipedia
Balovaptan: An Atypical Benzodiazepine With Unique Medicinal Potential - Tripsitter
Discovery of Balovaptan, a Vasopressin 1a Receptor Antagonist for the Treatment of Autism Spectrum Disorder | Journal of Medicinal Chemistry
Biomedicines | Free Full-Text | The Biology of Vasopressin
Discovery of Balovaptan, a Vasopressin 1a Receptor Antagonist for the Treatment of Autism Spectrum Disorder | Journal of Medicinal Chemistry
A randomized placebo-controlled pilot trial shows that intranasal vasopressin improves social deficits in children with autism | Science Translational Medicine
